Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg
Hepatorenal Syndrome
About this trial
This is an interventional treatment trial for Hepatorenal Syndrome
Eligibility Criteria
Inclusion Criteria:
1. Admission to intensive care unit (ICU) 2. Age >18 years old 3. Able to obtain informed consent obtained from the patient, from the patient's power of attorney, or from the next of kin 4. Must meet all major criteria based on the International Ascites Club definition and diagnostic criteria for Hepatorenal Syndrome:
- chronic or acute liver disease with advanced hepatic failure and portal hypertension;
- the serum creatinine is greater than 1. 5 mg/dL or 24 hour creatinine clearance of less than 40 ml/min;
- absence of shock, ongoing bacterial infection, and current or recent treatment with nephrotoxic drugs;
- absence of gastrointestinal fluid losses (repeated vomiting or intense diarrhea) or renal fluid losses;
- no sustained improvement in renal function defined as a decrease in serum creatinine to less than 1.5 mg/dL or increase in 24 hour creatinine clearance to 40 ml/min or more following diuretic withdrawal and expansion of plasma volume with 1.5 L of isotonic saline;
- proteinuria less than 500 mg/dL;
- no ultrasonic evidence of obstructive uropathy or parenchymal renal disease. 5. In addition, patients must meet the definition of HRS type I or HRS type I
- -HRS I defined by a rapid deterioration in kidney function with the serum creatinine increasing by more than 100% from baseline to greater than 2.5mg/dl within a two week period.
- -HRS II defined as: patients with refractory ascites with either a steady but moderate degree of functional renal failure (≥ 1.5mg/dl) or deterioration in kidney function that does not fulfill the criteria for HRS type I
Exclusion Criteria:
1. pre-existing continuous renal replacement therapy cannot or those initiated on dialysis during their hospital stay.
2. artificial liver support therapies 3. ongoing gastrointestinal bleeding 4. active surgical issues 5. pre-existing TIPS or TIPS placed during hospital stay 6. long standing hypertension 7. improvement in renal function after central blood volume expansion contraindications to norepinephrine (active myocardial event, ventricular arrhythmia, obstructive physiology, limb ischemia) 8. Pregnancy 9. Treating physicians refusing to enroll patient
Sites / Locations
- University of Louisville
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
MAP 65-70
MAP greater than or equal to 85
Goal MAP of 65-70
MAP greater than or equal to 85